ABX196 for Hepatocellular Carcinoma
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies agonists of these types of cells that demonstrate immune enhancing effects in cancer models.
Preclinical data showed that ABX196 enhanced anti-tumoral activity when used alone and in combination with anti-PD1 antibodies or doxorubicin.
ABX196 was selected for development because of its ability to direct the immune system towards tumors that respond sub-optimally to anti-PD1 antibodies and has demonstrated in mouse models an ability to potentiate the anti-tumoral response to chemotherapy.
A phase 1 clinical trial in healthy volunteers has been completed and showed safety and activation of iNKT cells. Based on these data, new immuno-oncology preclinical studies were conducted that demonstrated the potential of the product in oncology, in particular in turning tumors not responsive to anti-PD1 (cold) to tumors responsive to anti-PD1 (hot). The candidate is expected to move into clinical trials in HCC in Q1 of 2019.
As Abivax is focusing on the antiviral and anti-inflammatory therapeutic spaces and does not intend to play a role in the immuno-oncology field, Abivax is seeking to out-license this exciting product candidate.